Progress with infliximab biosimilars for inflammatory bowel disease

References

• van der Valk ME, Mangen MJ, Leenders M, et al. COIN study group and the Dutch initiative on Crohn and Colitis. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014 Jan;63(1):72–79.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Severs M, et al. COIN study group and the Dutch initiative on Crohn and Colitis. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016 Apr 21;11(4):e0142481.
   PubMedGoogle Scholar
• Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015 Feb 14;21(6):1728–1737.
   PubMed Web of Science ®Google Scholar
• van Deen WK, Van Oijen MG, Myers KD, et al. A nationwide 2010–2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747–1753.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology. 2012. Commissioning guide. [Cited 2016 Sep 01]. Available at: http://www.nice.org.uk/media/F95/42/UpdateTA247AndPsoriasisCG.pdf
   Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018 Jan 23. pii: gutjnl-2017-315568.
   PubMedGoogle Scholar
• Gulacsi L, Rencz F, Poor G, et al. Patients’ access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016;75:942–943.
   PubMed Web of Science ®Google Scholar
• Biosimilars in the EU 2017. Information guide for healthcare professionals. European Medicines Agency. [Cited 2017 May 30]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
   Google Scholar
• Christl L. Overview of the regulatory framework and FDA’s guidance the development and approval of biosimilar products in the US. [Cited 2017 Oct 25]. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM561565.pdf
   Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lovasz BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10:133–140.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim YH, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
   PubMedGoogle Scholar
• Kang YS, Moon HH, Lee SE, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951–956.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–1712.
   PubMed Web of Science ®Google Scholar
• Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016 Nov;10(11):1287–1293.
   PubMed Web of Science ®Google Scholar
• Kolar M, Duricová D, Brotlik M, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. J Crohns Colitis. 2016;10(suppl 1):S45–S46.
   Google Scholar
• Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary Observations. . J Crohns Colitis. 2016;10:127–132.
   PubMed Web of Science ®Google Scholar
• Komaki Y, Yamada A, Komaki F, et al. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Apr;45(8):1043–1057.
   PubMed Web of Science ®Google Scholar
• Choe YH, Lee SH, Park D, et al. Effectiveness and safety in Crohn’s disease patients who were treated with CT-P13. Gastroenterology. 2017 Apr;152(5, Supplement 1):S406.
   Google Scholar
• Gonczi L, Kb G, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017 Nov;23(11):1908–1915.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulatorto infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:444–447.
   PubMed Web of Science ®Google Scholar
• Bar-Yoseph H, Waterman M, Almog R, et al. Prevention of antidrug antibody formation to infliximab in Crohn’s patients with prior failure of thiopurines. Clin Gastroenterol Hepatol. 2017 Jan;15(1):69–75.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Gils A, Accossato P, et al. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018Jan21;11:1756283X17750355.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. PROSIT-BIO cohort. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017 Feb;23(2):233–243.
   PubMed Web of Science ®Google Scholar
• Armuzzi A, Fiorino G, Variola A, et al. A prolonged follow-up on the efficacy and safety of infliximab biosimilar CT-P13 in IBD across Italy: the PROSIT Cohort. Gastroenterology. 2017 April;152(5, Supplement 1):S108.
   Web of Science ®Google Scholar
• Kim YH, Ye BD, Pesegova M, et al. Phase III randomized, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn’s disease: 1-year maintenance and switching results. United Eur Gastroenterol J. 2017;5(Supplement 1).
   PubMedGoogle Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017 Jun 10;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Buer LC, Moum BA, Cvancarova M. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017 Mar 1;11(3):297–304.
   PubMed Web of Science ®Google Scholar
• Smits L, Grelack A, Derikx L, et al. Long-term clinical outcomes after switching from Remicade® to Biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2017 Nov;62(11):3117–3122.
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017 Jun 1;11(6):690–696.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology (Oxford). 2017 Oct 1;56(10):1771–1779.
   PubMed Web of Science ®Google Scholar
• Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017 Jan;76(1):58–64.
   PubMed Web of Science ®Google Scholar
• Biosimilars of infliximab. Generics and Biosimilars Initiative (GaBI) online. Available at: http://www.gabionline.net/Biosimilars/General/Biosimilars-of-infliximab. [Last updated 2017 Nov 10]
   Google Scholar
• Derzi M, Johnson TR, Shoieb AM, et al. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade® (Infliximab). Adv Ther. 2016 Nov;33(11):1964–1982.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease – an update. J Crohns Colitis. 2017 Jan;11(1):26–34.
   PubMed Web of Science ®Google Scholar
• Baji P, Gulacsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn’s disease across Europe. United Eur Gastroenterol J. 2018 Mar;6(2):310–321.
   PubMed Web of Science ®Google Scholar
• Rencz F, Gulacsi L, Pentek M, et al. Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):597–606.
   PubMed Web of Science ®Google Scholar
• Beilman CL, Ma C, McCabe C, et al. Cost-effectiveness of infliximab’s biosimilar CT-P13 compared to innovator infliximab for the management of Crohn’s disease. Gastroenterology. 2017 Apr;152(5, Supplement 1):S447.
   Web of Science ®Google Scholar
• Brodszky V, Rencz F, Péntek M, et al. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–125. Epub 2015 Jul 10.
   PubMed Web of Science ®Google Scholar
• Kim J, An Hong J, Kudrin A. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn’s disease in UK, Italy and France. J Crohn’s Colitis. 2015;9(1):S144–S145.
   Google Scholar
• Severs M, Oldenburg B, van Bodegraven AA, et al. Initiative of Crohn’s and Colitis. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017 Mar 1;11(3):289–296.
   PubMed Web of Science ®Google Scholar
• Adalimumab biosimilar ABP 501 shows similar efficacy, safety and immunogenicity. Generics and Biosimilars Initiative (GaBI) online. [Cited 2017 Jan 01]. Available at: http://www.gabionline.net/Biosimilars/Research/Adalimumab-biosimilar-ABP-501-shows-similar-efficacy-safety-and-immunogenicity
   Google Scholar
• Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017 Oct;76(10):1679–1687.
   PubMed Web of Science ®Google Scholar
• Papp K, Bachelez H, Costanzo A, et al. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomised, double-blind, 52-week, phase 3 study in moderate-to-severe plaque psoriasis patients. Br J Dermatol. 2017 Jul 28;177:1562–1574.
   Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase 3 randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate to severe rheumatoid arthritis. Arthritis Rheumatol. 2018 Jan;70(1):40-48.
   Web of Science ®Google Scholar
• Cohen S, Alonso-Ruiz A, Klimiuk PA, et al. FRI0189 Similar efficacy and safety of biosimilar candidate BI 695501 and Humira® reference product in patients with moderate to severe active RA: 24 week results from a Phase III clinical study (VOLTAIRE®-RA). Ann Rheum Dis. 76(Suppl 2).
   Google Scholar
• Ebbers H, Chamberlain P. Interchangeability. An insurmountable fifth hurdle? Gabi J. 2014;3:88–93.
   Google Scholar
• Gecse KB, Lakatos PL. Biosimilar monoclonal antibodies for inflammatory bowel disease: current comfort and future prospects. Drugs. 2016 Oct;76(15):1413–1420.
   PubMed Web of Science ®Google Scholar